Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer

3MO - Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)


03 Dec 2022


Mini Oral session: Breast cancer


Clinical Research

Tumour Site

Breast Cancer


Qingyuan Zhang


Annals of Oncology (2022) 33 (suppl_9): S1431-S1435. 10.1016/annonc/annonc1118


Q. Zhang1, K. Shen2, C. Song3, Q. Ouyang4, Z. Liu5, Q. Liu6, X. Wang7, Y. Yang8, C. Qian9, Z. Shao10

Author affiliations

  • 1 Department Of Medical Oncology, Harbin Medical University Cancer Hospital, 150040 - Harbin/CN
  • 2 Department Of Breast Oncology, Ruijin Hospital of Shanghai Jiaotong University, Shanghai/CN
  • 3 Department Of Breast Surgery, Fujian Medical University Union Hospital, 350001 - Fuzhou/CN
  • 4 Department Of Breast Cancer Medical Oncology, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 5 Department Of Breast Cancer Center, Henan Cancer Hospital, 450008 - Zhengzhou/CN
  • 6 Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 510120 - Guangzhou/CN
  • 7 Department Of Breast Oncology, Zhejiang Cancer Hospital - Cancer Research Institute, 310022 - Hangzhou/CN
  • 8 China Value, Evidence And Outcomes, Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai/CN
  • 9 Statistics, Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai/CN
  • 10 Department Of Breast Surgery, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN


Login to access the resources on OncologyPRO.

Abstract 3MO


Adjuvant abemaciclib (CDK4 & 6 inhibitor) plus ET demonstrated clinically meaningful improvement in invasive disease-free survival among Chinese pts with HR+, HER2-, node-positive, high-risk EBC in the monarchE phase III study. Here, we present data on PROs of Chinese pts at primary outcome analysis.


495 Chinese pts in safety population were included in PROs evaluation (abemaciclib + ET arm: 259; ET arm: 236). Health-related quality-of-life (FACT-B), ET symptoms (FACT-ES, 2 cognitive/3 bladder FACIT items), fatigue (FACIT-Fatigue) and symptom burden (FACT-B GP5) were assessed at randomization (baseline), 3/6/12/18/24 months on treatment and follow-up. Exploratory analyses assessed items reflecting common adverse events (AEs; diarrhea, fatigue, arthralgia, hot flushes), including frequency of scores for FACT-ES C5 “I have diarrhea”, and FACT-B GP5 “bothered by treatment side effect”. A mixed effect model for repeated measures (MMRM) compared summary and item scores by treatment arm. For the summary scores, a minimally important difference (MID) was defined as an effect size of a half standard deviation at baseline. For the item scores, a change of 1 was deemed meaningful.


More than 90% of pts completed the baseline and at least one postbaseline PRO questionnaires. The MMRM analysis showed numerically similar results for all summary scores and items scores between two arms, and the changes from baseline, except diarrhea, did not reach MID in both arms at each visit. Change from baseline for diarrhea was ≤1.12 for pts receiving abemaciclib and ≤0 for ET only. From 3 months onwards, most pts who experienced diarrhea in the abemaciclib arm reported having diarrhea “a little bit” or “somewhat”. The frequency of diarrhea decreased after discontinuation of abemaciclib. Most pts in both arms reported being bothered “a little bit” or “not at all” by treatment side effect.


The addition of abemaciclib to ET did not result in notable differences in overall PROs, suggesting a tolerable profile for abemaciclib in Chinese EBC pts. Increased frequency of diarrhea was consistent with the known manageable, reversible AE profile.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Eli Lilly and Company.


Eli Lilly and Company.


Y. Yang, C. Qian: Financial Interests, Personal and Institutional, Full or part-time Employment: Eli Lilly and Company. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.